Of note, the urokinase plasminogen activator system was shown in earlier immunohistochemistry studies to be upregulated in psoriasis, and uPA and plasmin having been proposed as potential therapeutic targets (Li et al, 2011; Rubina et al, 2017). The gene discussed is PLAU; the disease is psoriasis.